Health Effects of Increasing Muscle Activation While Sitting in Office Workers

NCT02855541 | Completed Results DMC

• 1 other identifier: UColoradoBoulder
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

Previous research suggests that prolonged sitting increases risk for cardiometabolic diseases and the risk factors associated with cardiometabolic diseases. However, no study to date has examined if a chronic intervention that breaks up prolonged sitting in a real-world environment results in a reduction in the metabolic risk factors associated with cardiometabolic diseases. Thus, the objective of this study is to examine the potential health benefits of breaking up sitting bouts throughout the workday using a small cycling device (DeskCycle) in office workers involved with jobs that require prolonged bouts of sitting. The investigators hypothesize that breaking up sitting will be associated with improvements in cardiometabolic disease risk factors. More specifically, the investigators hypothesize that breaking up sitting will decrease blood glucose during an oral glucose tolerance test (OGTT), increase cardiorespiratory fitness (VO2max), decrease blood pressure, decrease body fat, increase HDL cholesterol, and decrease LDL cholesterol, total cholesterol, and triglycerides.

Conditions

Blood Pressure

Keywords

Blood Glucose; Physical Fitness; Body Composition; Lipids

Outcome Measures

Primary Outcomes (2)

• Blood Glucose

  2-h Post Oral Glucose Tolerance Test Blood Glucose

  Measured after 4 weeks

• Maximum Oxygen Consumption

  Maximum oxygen consumption (VO2max) will be used to determine physical fitness

  Measured after 4 weeks

Secondary Outcomes (6)

• Systolic Blood Pressure

  Measured after 4 weeks

• HDL Cholesterol

  Measured after 4 weeks

• LDL Cholesterol

  Measured after 4 weeks

• Triglycerides

  Measured after 4 weeks

• Lean Mass

  Measured after 4 weeks

Study Arms (1)

Cycling intervention

EXPERIMENTAL

Participants will use a small cycling device (DeskCycle) at their workstation for 15 minutes every hour that they are at work.

Device: DeskCycle

Interventions

DeskCycle DEVICE

A small cycling ergometer that can fit under a desk at the workplace.

Cycling intervention

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Both males and females
• Subjects will need to be 18-55 years old
• Subjects will need to be sitting at least 6 hours/day on 5 days/week
• Subjects will need to be exercising less than 5 hour/week

You may not qualify if:

• Females that are pregnant or breast-feeding.
• Subjects must be free from any acute or chronic physical condition that would influence the outcome measures of the protocol. Examples include, but are not limited to advanced chronic disease states (chronic kidney, liver, heart, or lung disease), morbid obesity, emphysema, and an inability to use the legs for normal locomotion. Normality will be established on the basis of clinical history, physical exam, and vital signs. Any subject with a history of an uncontrolled metabolic disorder/disease or symptoms of active illness will be excluded from study. Any subject with a history of an uncontrolled metabolic disorder/disease such as diabetes (Type I or Type II) or symptoms of active illness will be excluded from study.
• Subjects will be excluded if they have a fasted blood glucose level \>126 mg/dl or a systolic blood pressure \>140 mmHg.
• Medical/psychiatric/sleep disorders history: any clinically significant unstable medical or psychological condition within the last year (treated or untreated).
• Drug use:
• Use of any medications, including over-the-counter and herbal products, that may affect metabolic function within 1 month prior to the study or need to use any of these medications at any time during the study (self-report by interview). Examples of potential medications that will exclude a subject include: beta-adrenergic blockers, sulfonylureas, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, and dipeptidyl peptidase IV inhibitors. Note, subjects may be tested at a later date.
• Use of any investigational drug within 1 month before the study

Sponsors & Collaborators

• University of Colorado, Boulder: lead

Study Sites (1)

University of Colorado Boulder

Boulder, Colorado, 80309, United States

Location

Limitations and Caveats

Participants were encouraged to cycle a set amount but this may not reflect how they would prefer to use the cycling device. In addition, the intervention was only 4 weeks long and more time may be needed to see improvements in the outcome measures.

Results Point of Contact

• Title: James Peterman, PhD
• Organization: University of Colorado Boulder

james.peterman@colorado.edu

303-735-0358

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Graduate Student

Study Record Dates

• First Submitted: July 29, 2016
• First Posted: August 4, 2016
• Study Start: August 1, 2016
• Primary Completion: June 1, 2017
• Study Completion: June 1, 2017
• Last Updated: November 13, 2018
• Results First Posted: November 13, 2018

Record last verified: 2018-11

Locations

US (1)